What’s Next for IMMUNOPRECISE ANTIBODIES LTD. ORDINARY S (OTCMKTS:IPATF) After Having Less Shares Shorted?

The stock of IMMUNOPRECISE ANTIBODIES LTD. ORDINARY S (OTCMKTS:IPATF) registered a decrease of 78.31% in short interest. IPATF’s total short interest was 1,800 shares in September as published by FINRA. Its down 78.31% from 8,300 shares, reported previously. With 13,100 shares average volume, it will take short sellers 0 days to cover their IPATF’s short positions.

The stock decreased 8.08% or $0.0361 during the last trading session, reaching $0.4109. About 1,850 shares traded. ImmunoPrecise Antibodies Ltd. (OTCMKTS:IPATF) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.

ImmunoPrecise Antibodies Ltd. provides custom hybridoma development services primarily in the United States and Canada. The company has market cap of $28.17 million. The firm primarily supplies custom antibodies for research and industrial applications. It currently has negative earnings. It also offers human antibody development, hybridoma development, rabbit monoclonal antibody development, recombinant protein expression and production, cryostorage, hybridoma sequencing, antibody generation, antibody purification, polyclonal development, and peptide production services.

More news for ImmunoPrecise Antibodies Ltd. (OTCMKTS:IPATF) were recently published by: Seekingalpha.com, which released: “ImmunoPrecise Antibodies extends partnership with TetraGenetics – Seeking Alpha” on April 09, 2019. Seekingalpha.com‘s article titled: “ImmunoPrecise creates Talem Therapeutics – Seeking Alpha” and published on April 04, 2019 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.